Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Recursion Pharmaceuticals, Inc.
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
Today 18:00 EST
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RXRX
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
December 03, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RXRX
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
November 20, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
EXAI
RXRX
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
November 12, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RXRX
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
October 22, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RXRX
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
October 02, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RXRX
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
September 03, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RXRX
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
August 08, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
EXAI
RXRX
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
June 24, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RXRX
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
April 16, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RXRX
Recursion Announces Plans to Open New Office in London
March 11, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RXRX
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
January 04, 2024
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RXRX
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
November 09, 2023
From
Recursion Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
RXRX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.